{"id":"NCT00500266","sponsor":"Pfizer","briefTitle":"Study Evaluating Safety of 13-Valent Pneumococcal Conjugate Vaccine in Healthy Elderly Subjects","officialTitle":"A Phase 3, Open-Label, Single-Arm Trial Evaluating the Safety, Tolerability, & Reactogenicity of a 13vPnC Vaccine in Ambulatory Elderly Adults Aged 68 Years & Older Who Received 1 or More Doses of 23vPS Vaccine at Least 3 Years Before Study Enrollment","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-05","primaryCompletion":"2009-04","completion":"2009-05","firstPosted":"2007-07-11","resultsPosted":"2011-09-16","lastUpdate":"2011-09-16"},"enrollment":1053,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"PREVENTION"},"conditions":["Pneumococcal Infections"],"interventions":[{"type":"BIOLOGICAL","name":"13-valent Pneumococcal Conjugate Vaccine (13vPnC)","otherNames":[]}],"arms":[{"label":"1","type":"EXPERIMENTAL"}],"summary":"To evaluate the safety of 13-valent pneumococcal conjugate vaccine (13vPnC) in elderly subjects who were vaccinated with one or more doses of 23-valent pneumococcal polysaccharide vaccine (23vPS) at least 3 years before study enrollment.","primaryOutcome":{"measure":"Percentage of Participants With Pre-specified Local Reactions","timeFrame":"Days 1 through 14","effectByArm":[{"arm":"13vPnC","deltaMin":14.3,"sd":null}],"pValues":[]},"eligibility":{"minAge":"68 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":3,"exclusionCount":4},"locations":{"siteCount":59,"countries":["United States","Germany","Sweden"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":10,"n":1049},"commonTop":["Pain (any)","Pain (mild)","Fatigue (any)","Fatigue (mild)","Headache (any)"]}}